» Authors » Susan M Efler

Susan M Efler

Explore the profile of Susan M Efler including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 4
Citations 142
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Cooper C, Ahluwalia N, Efler S, Vollmer J, Krieg A, Davis H
J Immune Based Ther Vaccines . 2008 Jun; 6:3. PMID: 18541039
Background: Chronic hepatitis C virus (HCV) infection results from weak or absent T cell responses. Pegylated-interferon-alpha (IFN-alpha) and ribavirin, the standard of care for chronic HCV, have numerous immune effects...
2.
McHutchison J, Bacon B, Gordon S, Lawitz E, Shiffman M, Afdhal N, et al.
Hepatology . 2007 Oct; 46(5):1341-9. PMID: 17929306
Unlabelled: CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter...
3.
Vicari A, Schmalbach T, Lekstrom-Himes J, Morris M, Al-Adhami M, Laframboise C, et al.
Antivir Ther . 2007 Aug; 12(5):741-51. PMID: 17713157
Unlabelled: CPG 10101 (ACTILON) is a novel potent and selective unmethylated cytidine-phosphate-guanosine (CpG)-containing oligodeoxynucleotide agonist of Toll-like receptor 9 (TLR9) being developed for the treatment of chronic infections such as...
4.
Krieg A, Efler S, Wittpoth M, Al Adhami M, Davis H
J Immunother . 2004 Nov; 27(6):460-71. PMID: 15534490
Subcutaneous injection of normal human volunteers with a B-class CpG oligodeoxynucleotide (ODN) TLR9 agonist, CPG 7909, induced a TH1-like pattern of systemic innate immune activation manifested by expression of IL-6,...